Samuel Kintz
PRESIDENT AND CEO · Enliven Therapeutics, Inc.
- 2024
- Nov 19, 2025
- 11
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Samuel Kintz files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ORBIMED ADVISORS LLC - $51.68M in ELVN purchases and sales in the last 12 months
- Mika K. Derynck - $9.56M in ELVN purchases and sales in the last 12 months
- Helen Louise Collins - $5.39M in ELVN purchases and sales in the last 12 months
- Joseph P. Lyssikatos - $4.71M in ELVN purchases and sales in the last 12 months
- Benjamin Hohl - $1.53M in ELVN purchases and sales in the last 12 months
- Anish Patel - $1.47M in ELVN purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Samuel Kintz?
Samuel Kintz is a corporate insider, tracked as PRESIDENT AND CEO of Enliven Therapeutics, Inc. (ELVN). InsiderAlpha holds 11 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Samuel Kintz last file a Form 4?
The most recent primary Form 4 on record is dated 19 November 2025, one of 11 filings going back to 2024.
Has Samuel Kintz been buying or selling stock?
Recorded transactions: 0 open-market purchases and 18 open-market sales ($2.39M) across all tracked filings.
